Back to User profile » Prof. Dr. Julia-Tatjana Maul
Papers published by Prof. Dr. Julia-Tatjana Maul:
Patient-Reported Well-Being in Value-Based Routine Care in Psoriatic Disease Using Tildrakizumab: 2-Year Data of the Phase IV POSITIVE Study
Mrowietz U, Sommer R, Reguiai Z, Gerdes S, Daudén E, Weger W, Maul JT, Naldi L, Ghislain PD, Laws PM, De Jong EMGJ, Mburu S, Koscielny V, Massana E, Sapena V, Domenech A, Kasujee I, Augustin M
Psoriasis: Targets and Therapy 2026, 16:590189
Published Date: 12 May 2026
Patient-Reported Well-Being in Value-Based Routine Care Using Tildrakizumab: 52-week Interim Data of the Phase IV Positive Study
Mrowietz U, Sommer R, Gerdes S, Reguiai Z, Weger W, Daudén E, Maul JT, Ghislain PD, Laws PM, Naldi L, De Jong E, Mburu S, Koscielny V, Massana E, Domenech A, Gaarn du Jardin K, Kasujee I, Augustin M
Psoriasis: Targets and Therapy 2025, 15:243-259
Published Date: 28 June 2025
Treatment of Psoriasis with II-17 Inhibitors: Comparison of Long-Term Effectiveness and Drug Survival of Secukinumab vs Ixekizumab in Real-World Practice
Lam J, Cazzaniga S, Seyed Jafari SM, Maul JT, Feldmeyer L, Bossart S, Yawalkar N, Heidemeyer K
Psoriasis: Targets and Therapy 2025, 15:71-84
Published Date: 27 March 2025
Effectiveness of Biologics, Patient-Reported Outcomes, and Clinical Photography in a Subset of Patients with Moderate-to-Severe Psoriasis: Week 12 Results from the Psoriasis Study of Health Outcomes (PSoHO)
Travaglini M, Maul JT, Kors C, Zaheri S, Gerwien J, Müller M, Brnabic A, Sabatino S, Schuster C, Tsai TF
Clinical, Cosmetic and Investigational Dermatology 2023, 16:2971-2983
Published Date: 20 October 2023
Limited clinical utility of HLA-Cw6 genotyping for outcome prediction in psoriasis patients under ustekinumab therapy: a monocentric, retrospective analysis
Anzengruber F, Ghosh A, Maul JT, Drach M, Navarini AA
Psoriasis: Targets and Therapy 2018, 8:7-11
Published Date: 23 March 2018